Reference desk / Entry
Liraglutide
Also listed as: Saxenda
Read the scope first. Then use the note and questions to examine what the evidence can answer.
- Scoped product status
- Approved product
- Evidence label
- Randomized evidence
- Status as of
Reference fields
References for these fields are listed together in Sources.
- Product and use scope
- Saxenda: weight management for eligible patients.
- Route context
- Subcutaneous injection.
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limitations
- Check other products separately.
- Safety
- The label warns about severe gastrointestinal reactions.
A question worth making clear
Before placing results from two reports side by side, check whether their outcome labels refer to the same measurement. Compare the definition, unit, assessment point, and way individual observations are combined. If a familiar word stands for different measures, note the difference beside the results instead of silently treating them as interchangeable. Decide together what would need to match for the intended comparison to make sense. This exercise can reveal that the reports are answering different questions, even when their headings appear to promise an answer about the same outcome.
- Do both reports define the outcome in a way that measures the same thing?
- Which differences in units or assessment points would matter to our comparison?
- What would need to match before we could interpret these results together?
Sources
Each date below belongs to the supplied source record. The references support the entry as a group.
- SAXENDA
NLM · Checked